Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have earned an average rating of “Buy” from the eleven brokerages that are covering the stock, MarketBeat Ratings reports. Ten investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $57.10.

MIRM has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Citigroup raised their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Robert W. Baird raised their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Finally, Leerink Partners raised their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 2,500 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $47.10, for a total transaction of $117,750.00. Following the transaction, the senior vice president now owns 2,426 shares in the company, valued at approximately $114,264.60. The trade was a 50.75 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Christopher Peetz sold 7,489 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $320,678.98. Following the sale, the chief executive officer now directly owns 119,359 shares in the company, valued at $5,110,952.38. This trade represents a 5.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,622 shares of company stock worth $1,398,791 in the last quarter. Company insiders own 22.87% of the company’s stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp boosted its holdings in shares of Mirum Pharmaceuticals by 19.9% during the third quarter. State Street Corp now owns 1,793,728 shares of the company’s stock worth $69,955,000 after purchasing an additional 297,511 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Mirum Pharmaceuticals by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock worth $12,798,000 after purchasing an additional 17,149 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Mirum Pharmaceuticals by 3.2% during the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock worth $36,519,000 after purchasing an additional 29,017 shares during the last quarter. GSA Capital Partners LLP boosted its holdings in shares of Mirum Pharmaceuticals by 791.7% during the third quarter. GSA Capital Partners LLP now owns 57,985 shares of the company’s stock worth $2,261,000 after purchasing an additional 51,482 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Mirum Pharmaceuticals by 25.5% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company’s stock worth $6,021,000 after purchasing an additional 29,545 shares during the last quarter.

Mirum Pharmaceuticals Price Performance

NASDAQ:MIRM opened at $48.88 on Monday. Mirum Pharmaceuticals has a one year low of $23.14 and a one year high of $50.00. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The stock has a market cap of $2.35 billion, a PE ratio of -24.20 and a beta of 0.98. The stock has a 50 day moving average price of $44.31 and a 200 day moving average price of $41.92.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $90.38 million during the quarter, compared to analysts’ expectations of $81.99 million. During the same quarter last year, the firm earned ($0.57) earnings per share. The business’s revenue for the quarter was up 89.4% on a year-over-year basis. Equities research analysts expect that Mirum Pharmaceuticals will post -1.44 EPS for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.